Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study

J Jiménez-Candil, J Bermejo, R Yotti, C Cortina, M Moreno, J L Cantalapiedra, M A García-Fernández

Objective: To determine the effects of angiotensin converting enzyme (ACE) inhibitors in hypertensive patients with aortic valve stenosis (AS).

Design: Observational, drug withdrawal, single blinded study, with randomisation of the order of tests.

Setting: Hypertension and asymptomatic AS.

Patients and interventions: 20 patients (aged 73 (9) years, valve area 0.7 (0.3) cm², left ventricular ejection fraction ≥ 45%) were enrolled. Each patient underwent two sets of tests (with and without taking the drug), each of which included clinical evaluation, Doppler echocardiogram, and symptom limited exercise echocardiography.

Main outcome measures: Functional and haemodynamic variables while taking and not taking ACE inhibitors.

Results: Drug intervention induced no change in patients' subjective functional class. While taking ACE inhibitors, patients had a lower systolic blood pressure (140 (18) mm Hg with ACE inhibitors vs 159 (12) mm Hg without ACE inhibitors, p = 0.02), a higher mean pressure gradient (34 (15) mm Hg vs 28 (18) mm Hg, p = 0.037), and a higher left ventricular stroke work loss (19 (6)% vs 14 (10)%, p = 0.009). Other baseline functional and haemodynamic parameters were unmodified. Five patients had an abnormal blood pressure response during one of the exercise tests (two patients while taking the drug and three patients while not taking the drug). When taking ACE inhibitors, patients had a higher stroke volume at peak stress (59 (1) ml vs 54 (2) ml, p = 0.046). All other stress variables remained constant.

Conclusions: In AS, the afterload relief caused by ACE inhibitors is blunted by a parallel increase in the pressure gradient. However, ACE inhibitors favourably affect stress haemodynamic function in most hypertensive patients with AS and should not be discontinued.

Aortic valve stenosis (AS) affects 2–7% of the elderly population.1 Almost one third of patients with AS have concomitant systemic hypertension.2 Because patients with AS are known to be at a high risk for adverse cardiovascular events,3 control of blood pressure should be of major relevance in this population.

Lowering blood pressure is particularly difficult in patients with AS because of the complex adaptation of the cardiovascular system to left ventricular (LV) outflow obstruction. Drugs that are safely used to treat isolated hypertension may cause adverse cardiovascular effects in patients with a fixed cardiac output. Diuretics, β and α blocking agents, calcium antagonists, and inhibitors of the renin–angiotensin–aldosterone system need to be used with caution by patients with AS, since they are particularly sensitive to manipulations of preload, contractility, and vasmotor tone.3

Angiotensin converting enzyme (ACE) inhibitors are well established drugs for treating hypertension. ACE inhibitors have also been shown to reduce mortality and morbidity in some patient groups, such as those with impaired systolic function,3 with diabetic nephropathy,4 or at high risk for cardiovascular events.5 Importantly, these favourable effects of ACE inhibitors are independent of their effect on blood pressure. Experimental evidence suggests additional potential benefits of ACE inhibitors on AS. The identification of ACE and angiotensin activity in the tissue of degenerative aortic valves indirectly suggests a potential role of ACE inhibitors in slowing disease progression.6 Also, ACE activity is known to modulate the myocardial fibrosis caused by the systolic overload of AS.7 8 Hence, ACE inhibitors may induce more favourable ventricular remodelling.

Regardless of all these potential benefits, AS is considered a classic contraindication to prescribing ACE inhibitors, as is recognised in some textbooks11 12 and in manufacturers’ prescribing information (for Vasotec, Lotensin, Zestril, Altace, and Monopril: www.pdr.net/pdrnet/librarian; and for Capoten: www.rxlist.com). Very recent evidence suggests that ACE inhibitors can be used safely in AS9 10 and may even be beneficial for patients with symptomatic disease.14 15 We designed a drug withdrawal, single blinded, transversal, prospective enrolment study to assess the haemodynamic effects of ACE inhibitors in hypertensive patients with AS. Cardiovascular haemodynamic effects were analysed non-invasively by exercise Doppler echocardiography.

METHODS

Study population

The study was approved by the institutional ethics committee and written informed consent was obtained from all patients. Eligible participants were screened among all patients referred to our laboratory with AS diagnosed on echocardiographic examination. Inclusion criteria for the study were moderate or severe AS (peak aortic velocity ≥ 2.5 m/s and...
aortic valve area \( \leq 1.2 \text{ cm}^2 \)) and concomitant treatment with an ACE inhibitor for at least three months, prescribed for arterial hypertension. Exclusion criteria were the presence of symptoms related to AS, existence of any other valvar stenosis or regurgitation other than mild (1+), previous cardiac surgery, and absence of a suitable ultrasonic window. After consecutive review of the medical records and telephone interviews with all potential candidates, 27 eligible patients were identified. Five patients did not provide written informed consent. Although 22 patients were randomly assigned to the treatment regimens, one patient did not finish the study. His ejection fraction was normal and mean transvalvar pressure gradient was 70 mm Hg. After withdrawal of 10 mg/day of enalapril, although he denied any AS symptoms, the exercise test (Bruce protocol) was prematurely interrupted at the fourth minute because of dyspnea. The blood pressure response was normal. Although he was informed by the investigators of the need for close follow up, he decided to abandon the study. Another patient had pneumonia and her physician discontinued the ACE inhibitor. Therefore, 20 patients completed the study protocol (table 1).

**Study design and clinical data**

Each patient underwent two sets of tests (with and without taking the drug) each of which included a full clinical evaluation, Doppler echocardiogram, and symptom limited stress echocardiography. To minimise the potential confusion phenomenon, participants were randomly allocated to the order in which each set of tests was performed (ACE inhibitors/no ACE inhibitors). The investigators who performed and measured the Doppler echocardiographic and exercise examinations were blinded to this order. ACE inhibitor drug withdrawal and reintroduction were progressive, with a daily dose reduction or increase equivalent to 1.25 mg of enalapril. Once the drug withdrawal or reintroduction scheme was completed, the second study was delayed for a period equivalent to five half lives of each drug. Patients who were not taking ACE inhibitors in the first phase received the first dose two hours after the first set of examinations was completed. Blood pressure was measured daily during the three days before each set of tests. Subjective functional class was assessed by the specific activity scale questionnaire. Approximate dose equivalents were calculated based on enalapril as the reference, as indicated for the treatment of hypertension.

**Doppler echocardiography**

Doppler echocardiograms were recorded digitally with a phased array ultrasound scanner (Acuson Sequoia 256, Siemens, Erlangen, Germany). Ultrasound images and Doppler spectrograms were obtained from standard parasternal, apical, subcostal, and suprasternal views. LV volumes and ejection fraction were measured from biplane four and two chamber apical views.

The methods used to measure stroke volume, cardiac output, mean transvalvar pressure gradient, and aortic valve area, as well as their reproducibility values, have been previously reported for our institution. Systemic vascular resistance was derived from Doppler derived cardiac output. LV end systolic wall stress (ESS) was calculated as follows:

\[
\text{ESS} = \frac{\text{LVPs} \cdot r_s}{2h_s \left(1 + \frac{h_s}{2r_s}\right)}
\]

where LVPs is peak LV pressure (systolic blood pressure + peak transvalvar instantaneous pressure gradient), \( r_s \) is the radius of the LV cavity in systole, and \( h_s \) is LV posterior wall thickness at end systole. Stroke work loss (SWL) was calculated as follows:

\[
\text{SWL} = 100 \frac{\text{MeanG}}{\text{MeanG} + \text{SBP}}
\]

where MeanG is the mean pressure gradient and SBP is systolic blood pressure. All measurements were averaged from four to six beats for patients in sinus or pacemaker rhythms and from six to 10 beats for patients in atrial fibrillation.

### Table 1 Baseline clinical data

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>SAS</th>
<th>CAD</th>
<th>Rhythm</th>
<th>LVEF (%)</th>
<th>Drug</th>
<th>Dose (mg/day)</th>
<th>DE (mg/day)</th>
<th>Indexed DE (mg m²/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>68</td>
<td>Female</td>
<td>II</td>
<td>No</td>
<td>AF</td>
<td>56</td>
<td>Enalapril</td>
<td>5</td>
<td>5</td>
<td>3.2</td>
</tr>
<tr>
<td>2</td>
<td>45</td>
<td>Female</td>
<td>I</td>
<td>No</td>
<td>Sinus</td>
<td>65</td>
<td>Enalapril</td>
<td>5</td>
<td>5</td>
<td>3.4</td>
</tr>
<tr>
<td>3</td>
<td>70</td>
<td>Male</td>
<td>I</td>
<td>Yes</td>
<td>AF</td>
<td>60</td>
<td>Enalapril</td>
<td>20</td>
<td>20</td>
<td>10.8</td>
</tr>
<tr>
<td>4</td>
<td>75</td>
<td>Male</td>
<td>I</td>
<td>No</td>
<td>Sinus</td>
<td>50</td>
<td>Captopril</td>
<td>50</td>
<td>6.6</td>
<td>3.6</td>
</tr>
<tr>
<td>5</td>
<td>55</td>
<td>Male</td>
<td>II</td>
<td>No</td>
<td>Sinus</td>
<td>69</td>
<td>Captopril</td>
<td>50</td>
<td>6.6</td>
<td>3.5</td>
</tr>
<tr>
<td>6</td>
<td>74</td>
<td>Male</td>
<td>I</td>
<td>Yes</td>
<td>AF</td>
<td>65</td>
<td>Captopril</td>
<td>75</td>
<td>10</td>
<td>5.5</td>
</tr>
<tr>
<td>7</td>
<td>67</td>
<td>Male</td>
<td>II</td>
<td>Yes</td>
<td>AF</td>
<td>45</td>
<td>Enalapril</td>
<td>20</td>
<td>20</td>
<td>10.6</td>
</tr>
<tr>
<td>8</td>
<td>73</td>
<td>Male</td>
<td>II</td>
<td>Yes</td>
<td>AF</td>
<td>60</td>
<td>Lisinopril</td>
<td>20</td>
<td>20</td>
<td>10.5</td>
</tr>
<tr>
<td>9</td>
<td>73</td>
<td>Female</td>
<td>II</td>
<td>No</td>
<td>Sinus</td>
<td>45</td>
<td>Lisinopril</td>
<td>5</td>
<td>5</td>
<td>2.7</td>
</tr>
<tr>
<td>10</td>
<td>65</td>
<td>Female</td>
<td>III</td>
<td>No</td>
<td>Sinus</td>
<td>67</td>
<td>Enalapril</td>
<td>20</td>
<td>20</td>
<td>11.9</td>
</tr>
<tr>
<td>11</td>
<td>80</td>
<td>Male</td>
<td>I</td>
<td>No</td>
<td>Sinus</td>
<td>63</td>
<td>Perindopril</td>
<td>4</td>
<td>10</td>
<td>5.2</td>
</tr>
<tr>
<td>12</td>
<td>83</td>
<td>Male</td>
<td>I</td>
<td>No</td>
<td>Sinus</td>
<td>63</td>
<td>Cilazapril</td>
<td>10</td>
<td>30</td>
<td>16.0</td>
</tr>
<tr>
<td>13</td>
<td>82</td>
<td>Male</td>
<td>I</td>
<td>Yes</td>
<td>Sinus</td>
<td>70</td>
<td>Lisinopril</td>
<td>20</td>
<td>20</td>
<td>10.3</td>
</tr>
<tr>
<td>14</td>
<td>84</td>
<td>Female</td>
<td>II</td>
<td>No</td>
<td>Pacemaker</td>
<td>65</td>
<td>Lisinopril</td>
<td>5</td>
<td>5</td>
<td>2.7</td>
</tr>
<tr>
<td>15</td>
<td>78</td>
<td>Male</td>
<td>II</td>
<td>No</td>
<td>AF</td>
<td>45</td>
<td>Captopril</td>
<td>37.5</td>
<td>5</td>
<td>2.5</td>
</tr>
<tr>
<td>16</td>
<td>68</td>
<td>Male</td>
<td>I</td>
<td>No</td>
<td>Sinus</td>
<td>66</td>
<td>Captopril</td>
<td>25</td>
<td>3.3</td>
<td>1.6</td>
</tr>
<tr>
<td>17</td>
<td>72</td>
<td>Male</td>
<td>I</td>
<td>No</td>
<td>Sinus</td>
<td>70</td>
<td>Captopril</td>
<td>100</td>
<td>13.3</td>
<td>7.2</td>
</tr>
<tr>
<td>18</td>
<td>74</td>
<td>Male</td>
<td>I</td>
<td>No</td>
<td>Sinus</td>
<td>70</td>
<td>Springol</td>
<td>6</td>
<td>10</td>
<td>5.8</td>
</tr>
<tr>
<td>19</td>
<td>72</td>
<td>Female</td>
<td>II</td>
<td>No</td>
<td>Sinus</td>
<td>65</td>
<td>Enalapril</td>
<td>20</td>
<td>20</td>
<td>11.6</td>
</tr>
<tr>
<td>20</td>
<td>73</td>
<td>Female</td>
<td>I</td>
<td>No</td>
<td>Sinus</td>
<td>65</td>
<td>Enalapril</td>
<td>20</td>
<td>20</td>
<td>11.6</td>
</tr>
<tr>
<td>Median</td>
<td>73</td>
<td>65</td>
<td>10</td>
<td>5.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dose equivalents (DE) were calculated with enalapril used as reference. Indexed dose equivalents were calculated by dividing dose equivalents by body surface area.

AF, atrial fibrillation; CAD, coronary heart disease; IQR, interquartile range; LVEF, left ventricular ejection fraction; SAS, specific activity scale.
Exercise stress echocardiography
A Bruce or a Naughton (two patients with impaired exercise tolerance) treadmill protocol was used for all except three patients who were unable to perform the test because of functional impairment. Blood pressure was measured non-invasively every minute, as recommended. Prespecified criteria for interrupting the exercise test were appearance of symptoms, fall in or inadequate (≤ 10 mm Hg) progression of systolic blood pressure, hypertensive response, frequent ventricular extrasystoles, ventricular tachycardia, bradycardia, new left bundle branch block, or ST segment depression ≥ 1.5 mm.

Statistical analysis
A sample size of 16 was calculated to detect a one metabolic equivalent (MET) difference between exercise tests performed with and without ACE inhibitors in a repeated measures design, assuming a standard deviation of one MET and α and β errors of 0.05 and 0.20, respectively.

Individual data are reported with a single identification label in all tables and figures, allowing tracking of each patient’s response across the whole report. Odd number labels identify patients studied with and then without ACE inhibitors. Even number labels identify patients studied in the reverse order. Because most variables are not normally distributed, they are described as median (interquartile range) and compared by exact Wilcoxon paired signed rank tests (S-Plus version 2000, Insightful Inc, Seattle, Washington, USA). Significance was assumed at p < 0.05.

RESULTS
Table 1 summarises baseline clinical and echocardiographic data. The study group consisted mostly of elderly patients with severe asymptomatic disease. Although some patients’ specific activity scale was > 1, their functional impairment was not attributed to AS either by the referring physician or by the investigators.

Changes related to ACE inhibitor withdrawal
Drug withdrawal and reintroduction were well tolerated by all patients, and no patient’s specific activity scale score was modified during the drug intervention period. Table 2 and fig 1 show changes in baseline haemodynamic parameters related to drug withdrawal. While taking ACE inhibitors, patients had a lower systolic blood pressure, whereas their diastolic blood pressure did not change. A higher transvalvar pressure gradient while taking ACE inhibitors was observed, whereas aortic valve area was unmodified (fig 1). As a consequence of the reciprocal changes in blood pressure and pressure gradient, LV percentage stroke work loss was higher while patients were taking ACE inhibitors (19 (6)% v 14 (10)%, respectively, p = 0.009).

Stress induced haemodynamic changes
Withdrawal of ACE inhibitors induced no changes either in exercise duration (7.0 (2.3) minutes v 7.0 (4.1) minutes, p = 0.4) or in final energy expenditure (fig 2). Although systolic blood pressure and pressure gradient at peak exercise were not modified by the drug intervention, patients had a higher stroke volume during stress while taking ACE inhibitors (fig 2). Also, a trend towards lower diastolic blood pressure at peak stress was observed while patients were not taking ACE inhibitors. The amount of the exercise induced rise in systolic blood pressure and of the decrease in systemic vascular resistance was unmodified by the drug intervention, whereas a trend towards greater increase in stroke volume was observed while patients were taking ACE inhibitors (p = 0.1) (fig 3). The modification induced by ACE withdrawal in stroke volume was closely related to its effect on systemic vascular resistance, both at baseline and during exercise (fig 4).

Abnormal exercise blood pressure responses
An abnormal exercise induced blood pressure response (fall or failure to rise) was observed in five stress tests from five patients (fig 3A). Two patients had an abnormal blood pressure response while taking ACE inhibitors, which was not reproduced when the drug was discontinued (numbers 15 and 16, fig 3). Excessive vasodilatation was the cause of one of these abnormal responses (number 15, fig 3C), whereas a fall in stroke volume was the cause of the other one (number 16, fig 3B). Remarkably, three patients had an abnormal response while not taking ACE inhibitors that was not observed while they were taking the drug (numbers 1, 5, and 18, fig 3A). The mechanisms were a severe fall in vascular resistance in one patient (number 1, fig 3C) and a combined failure to increase stroke volume and decrease in resistance in the other two (numbers 5 and 18, figure 3B, C).

DISCUSSION
ACE inhibitors in AS
ACE inhibitors have been classically contraindicated in the presence of AS. In patients with a fixed outflow obstruction, a reduction in systemic vascular resistance is not followed by a proportional increase in cardiac output. Therefore, it is believed that excessive vasodilatation may cause a dangerous fall in coronary or brain perfusion pressure, leading to exercise related symptoms of angina, syncope, or even sudden death. This hypothesis is indirectly based on evidence of a limited coronary flow reserve in patients with AS.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Haemodynamic data during and after withdrawal of treatment with angiotensin converting enzyme (ACE) inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment with ACE</strong></td>
<td><strong>After ACE withdrawal</strong></td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>68 (29)</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>140 (18)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>80 (10)</td>
</tr>
<tr>
<td>Stroke volume (ml)</td>
<td>56 (19)</td>
</tr>
<tr>
<td>Cardiac output (l/min)</td>
<td>3.7 (2.6)</td>
</tr>
<tr>
<td>Systemic vascular resistance (dyn s cm⁻¹)</td>
<td>2.290 (1.059)</td>
</tr>
<tr>
<td>Mean pressure gradient (mm Hg)</td>
<td>34 (15)</td>
</tr>
<tr>
<td>Aortic valve area (cm²)</td>
<td>0.66 (0.39)</td>
</tr>
<tr>
<td>LV and systolic wall stress (kdyne/cm²)</td>
<td>14.0 (8.7)</td>
</tr>
</tbody>
</table>

Data presented as mean (IQR).
*Exact Wilcoxon paired signed rank test; †calculated with parametric significance tests assuming normally distributed data (significance can be reached with a smaller sample when non-parametric exact tests are used).
LV, left ventricular.

www.heartjnl.com
However, it is not unusual in everyday practice for hypertensive patients with severe AS to be taking ACE inhibitors for a long time with no symptoms or events. On this basis, we designed this pilot study to quantify the functional and haemodynamic effects related to ACE inhibitor drug withdrawal in this particular population.

Only a few studies have previously assessed the effects of ACE inhibitors in AS. Martínez Sanchez et al.13 analysed the acute haemodynamic effects of captopril administration in 22 patients with severe AS. By using right heart catheterisation, these authors observed beneficial haemodynamic effects such as a decrease in systemic vascular resistance and an increase in cardiac output; unfortunately, neither valvar nor coronary haemodynamic effects were specifically analysed in their study. Recently, a pilot blinded, randomised, placebo controlled study assessed the haemodynamic and functional effects in AS patients with impaired LV systolic function: as peripheral resistance decreased, systemic vascular resistance and mean blood pressure increased.14

Intracoronary administration of enalapril has been shown to improve diastolic function acutely in patients with AS.28 Also, some other potential beneficial effects justify a controlled trial on the role of ACE inhibition in patients with AS. Extracoronary administration of enalapril has been shown to improve diastolic function acutely in patients with AS.26 Also, experimental data indicate that activation of the renin–angiotensin–aldosterone system contributes to cardiac fibrosis in animals and patients with AS and may be associated with unfavourable haemodynamic effects.27 Furthermore, ACE and angiotensin II are also present in the extracellular matrix of degenerative aortic valves with stenotic lesions and may have a role in lesion development and progression.8 Consequently, some investigators have questioned the contraindication of ACE inhibitors in AS in situations of concomitant hypertension, asymptomatic status, or heart failure.14 29 10

**Figure 1** Baseline haemodynamic data. Distributions are shown for (A) systolic blood pressure, (B) mean transvalvar pressure gradient, and (C) aortic valve area. In each panel, the left column shows values for patients while taking angiotensin converting enzyme (ACE) inhibitors and the right column shows values during drug withdrawal. Individual data are presented by a single identifier. Odd numbers identify patients randomly selected to be studied first while taking the drug and even numbers identify patients studied first without taking ACE inhibitors. Each box represents the interquartile distance and the white line represents the median. The shaded zone represents the 95% confidence interval for the median and the whiskers represent the limits of each distribution.

**Extrinsic and intrinsic load in AS**

Interestingly, we observed a significant decrease in the transvalvar pressure gradient while patients were not taking the ACE inhibitor drug, reciprocal to their increase in blood pressure. Nitroprusside had an identical effect in patients with AS with impaired LV systolic function: as peripheral...
The present study illustrates how modification of the pressure gradient blunts the response induced by vasodilators in systolic LV pressure and, consequently, in global end systolic stress. Reciprocal changes in the transvalvar pressure gradient and blood pressure are the consequence of the well characterised complementary and competitive interaction between intrinsic and extrinsic systolic load observed in situations of LV outflow obstruction. As shown in a recent study, the transvalvar pressure gradient rose when the resistance decreased, the transvalvar pressure gradient rose. The reciprocal changes in the transvalvar pressure gradient and blood pressure are the consequence of the well characterised complementary and competitive interaction between intrinsic and extrinsic systolic load observed in situations of LV outflow obstruction.

Figure 2 Haemodynamic data during exercise. Distributions are shown for peak exercise (A) systolic and (B) diastolic blood pressure, (C) mean transvalvar pressure gradient, (D) stroke volume, (E) systemic vascular resistance, and (F) final energy expenditure. Data are presented as in fig 1.
animal study, an intervention on aortic pressure alters transvalvar flow rate and, if valve area remains constant, modifies the transvalvar gradient in parallel. Further studies are required to clarify the basis of the vascular–valvar–ventricular coupling, since other mechanisms of interaction have been proposed.

The present study shows that patients with significant AS do not have a truly fixed stroke volume. Instead, modifying the vasodilator treatment had a direct effect on stroke volume, as fig 4 shows. The increase in peripheral resistance induced by drug withdrawal was followed by a reciprocal decrease of stroke volume, even in patients with critical AS and normal LV systolic function. This finding is in agreement with the hypothesis of the double loaded LV, according to which the extrinsic systolic load remains as a major determinant of ventricular performance, even in the presence of a severe outflow obstruction. Consequently, we believe that these potentially harmful haemodynamic effects of vasodilators in AS should be considered for the selection of the specific ACE inhibitor drug and dose to be tested in future clinical trials.

**Implications for assessing disease progression**

The effect of vasodilators on non-flow corrected indices of severity such as transvalvar velocity, pressure gradient, or LV stroke work loss obviously needs to be taken into account if a placebo controlled study is designed to assess the impact of ACE inhibitors on disease progression. It is noteworthy that a number of longitudinal studies have shown these non-flow corrected indices to be the best predictors of outcome in patients with AS. In asymptomatic patients, higher values of pressure gradient, aortic jet velocity, and stroke work loss are known to be associated with earlier development of symptoms, need for valve replacement, and cardiovascular death. Furthermore, for a similar degree of valvar obstruction, a higher stroke volume has been shown to correlate directly with more rapidly progressing AS. Our study shows that ACE inhibitors, by augmenting flow rate, modify all non-flow corrected indices of severity. Consequently, we believe that these potentially harmful haemodynamic effects of vasodilators in AS should be considered for the selection of the specific ACE inhibitor drug and dose to be tested in future clinical trials.

**The role of exercise testing in AS**

The role of exercise testing has been increasing in importance in guiding management of patients with AS. Hypotension or a failure to increase blood pressure during exercise correlates with a poor outcome in patients with AS and is accepted as a class II-A recommendation for valve surgery by some investigators and scientific committees. However, the reproducibility and the effect of vasodilator drugs on the haemodynamic response to exercise had never been assessed in AS. It is remarkable that all the patients in our study who had an abnormal blood pressure response during exercise also had a normal response either in the previous or in the following test. The abnormal blood pressure response was observed in three patients in their first study and in two patients in their second. We believe that the lack of reproducibility of the abnormal blood pressure response is most probably related to the drug intervention, since the confusing effect related to training was controlled by randomisation. The findings of our study suggest that the results of exercise testing need to be interpreted taking into account patients’ medication. If surgery in an asymptomatic patient is being considered on the basis of an abnormal haemodynamic response during an exercise test, the examination may require reassessment after the drug prescription is modified.

![Figure 3 Haemodynamic changes induced by exercise.](http://heart.bmj.com/)

(A) systolic blood pressure, (B) stroke volume, and (C) systemic vascular resistance are shown. Data are presented as in fig 1.
ACE inhibitors in aortic stenosis

needed to be enrolled to find significant differences in baseline haemodynamic variables. Following a pathophysiological pilot design, the purpose of the study is obviously far from that of a prospective drug intervention placebo controlled study. The fact that all patients were already taking the drugs for long periods before enrolment obviously causes a selection bias regarding tolerability. However, we believe our results may help to clarify the expected acute benefits and risks related to the use of ACE inhibitors in hypertensive patients with AS. For this purpose, we believe the sample size data that we provided may be helpful.

Differences in the specific compound and doses of ACE inhibitor drugs may have been responsible for the scattered effects observed in the study. Although we attempted to analyse an overall haemodynamic class effect for ACE inhibitors, the particular agents may not all behave identically.

Conclusions

Hypertensive patients with AS should not discontinue ACE inhibitors. In AS, the afterload reduction caused by ACE inhibitors is partially blunted by a parallel increase in the transvalvar pressure gradient. However, ACE inhibitors favourably affect stress haemodynamic variables in most hypertensive patients with AS. Prospective randomised studies to define the role of ACE inhibitors in AS are warranted.

ACKNOWLEDGMENTS

We thank all the personnel of the Echocardiography and Exercise Test Laboratories for their collaboration throughout the study.

Authors’ affiliations

J Jiménez-Candil*, J Bermejo, R Yotti, C Cortina, M Moreno, J J Cantalapiedra, M A García-Fernández, Department of Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

*Current address: Department of Cardiology, Hospital Clinico, Salamanca, Spain

Potential conflicts of interest None to disclose.

REFERENCES

Thebesian venous lake

A 50 year old woman with end stage renal disease status post renal transplant presented with chest pain and was found to have coronary artery disease on coronary angiography. During performance of a left ventriculogram with a hand injection using a JR4 catheter, serendipitous cannulation and injection of a large thebesian vein occurred with prompt visualisation of cardiac veins and the coronary sinus. There was a large thebesian ‘venous lake’ connection between the endocardial surface of the ventricle and the coronary sinus (panel). Such ‘venous lake’ connections have not been reported before. Thebesian veins can be communications between the capillary bed to the ventricles, direct arterial connection to the ventricles or venoluminal vessels, or direct communication from the coronary vein into the ventricles. Venoluminal thebesian veins are thought to be more common in the atria than in the ventricle, and more common in the right ventricle than the left ventricle. Direct cannulation of the thebesian vein via a JR4 catheter in the left ventricle was serendipitously achieved. This RAO projection shows a large thebesian ‘venous lake’ connecting the ventricular lumen to the cardiac veins and antegrade filling of the coronary sinus is demonstrated.

R Aqel
G J Zoghbi
raed.aqel@med.va.gov

www.heartjnl.com

REFERENCES


IMAGES IN CARDIOLOGY

doi: 10.1136/hrt.2004.058958
Thebesian venous lake

R Aqel, R Gupta and G J Zoghbi

*Heart* 2005 91: 1318
doi: 10.1136/hrt.2004.058958

Updated information and services can be found at:
http://heart.bmj.com/content/91/10/1318

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/